Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSCPA.L Regulatory News (SCPA)

  • There is currently no data for SCPA

Trading Statement

12 Apr 2018 07:00

RNS Number : 6330K
Scapa Group PLC
12 April 2018
 

 

12 April 2018

 

Scapa Group plc ("Scapa" or "the Group")

 

Year-end trading update

 

Scapa Group plc (AIM: SCPA) is today providing an unaudited year end update for the twelve months ended 31 March 2018.  

 

The Group performed well and the good progress reported in the Interim Results has continued. Overall Group results are in line with the improved expectations outlined in the Group's October trading update.

Healthcare: Revenues grew 3.8% for the year, despite currency headwinds in H2. Sales growth in H2 was strong at 6.8% on a constant currency basis. Margins for the year are expected to be above 15% reflecting the investment in the integration of two technology transfers completed during the year.

Industrial: Industrial continues to deliver on its asset optimisation strategy. Industrial margin further improved driven by the benefit of Asian restructuring and more efficient cost to serve. The Markel acquisition is complete and site consolidations are underway.

Healthy cash flow in the period ensured the Group ended the year with net debt of £3.8m, after the acquisition of Markel Industries for US$10.2m (£7.6m) and BioMed Laboratories LLC for US$19m (£13.6m).

Heejae Chae, CEO commented:

"This year we have delivered another set of strong results, and completed two acquisitions: Markel, our first Industrial acquisition, and BioMed, our first Healthcare acquisition outside adhesive technology. We also completed two technology transfers in Healthcare as we execute our growth strategy. I believe there is clear potential, in both Healthcare and Industrial, to further improve performance through organic growth, efficiency and acquisitions.

It is with great sadness that we announced yesterday a fatal accident at the Dunstable facility in the UK. I join with all of my colleagues and fellow directors in expressing our sincere condolences to the family and friends of the deceased."

Scapa expects to report its full year results on 22 May 2018.

This announcement contains inside information.

For further information:

Scapa Group plc Heejae Chae - Chief Executive Tel: 0161 301 7430

Graham Hardcastle - Finance Director

 

Numis Securities Limited Mark Lander, Richard Thomas Tel: 020 7260 1000

(Nominated Adviser/Joint Broker)

 

Berenberg Chris Bowman Tel: 020 3207 7800

(Joint Broker)

 

Weber Shandwick Financial PR Nick Oborne Tel: 0207 067 0000

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTFKDDPPBKDBQD
Date   Source Headline
12th Jun 20191:16 pmRNSDirector/PDMR Shareholding
12th Jun 20199:16 amRNSHolding(s) in Company
11th Jun 201910:28 amRNSHolding(s) in Company
10th Jun 20192:50 pmRNSAnnual Report and Notice of AGM
10th Jun 201910:05 amRNSHolding(s) in Company
10th Jun 20197:00 amRNSBoard update and additional information
3rd Jun 20194:32 pmRNSHolding(s) in Company
3rd Jun 20197:00 amRNSNotice of Termination of Material Contract
31st May 20199:19 amRNSTotal Voting Rights
28th May 201910:57 amRNSHolding(s) in Company
22nd May 20192:11 pmRNSHolding(s) in Company
21st May 20197:00 amRNSHeejae Chae to step down as Group CEO of Scapa
21st May 20197:00 amRNSScapa Group: Preliminary Results
30th Apr 20199:33 amRNSTotal Voting Rights
26th Apr 20192:21 pmRNSHolding(s) in Company
25th Apr 20192:15 pmRNSHolding(s) in Company
11th Apr 20197:00 amRNSYear-end trading update
29th Mar 20198:50 amRNSTotal Voting Rights
6th Mar 20194:12 pmRNSDirector/PDMR Shareholding
6th Mar 20199:43 amRNSPDMR Notification
28th Feb 20193:23 pmRNSTotal Voting Rights
12th Feb 20194:53 pmRNSDirector/PDMR Shareholding
8th Feb 20194:38 pmRNSDirector/PDMR Shareholding
25th Jan 20198:00 amRNSBlock listing Interim Review
23rd Jan 20197:00 amRNSCapital Markets Day
22nd Jan 20197:00 amRNSDirectorate Change
31st Dec 20189:08 amRNSTotal Voting Rights
21st Dec 201810:16 amRNSDirector/PDMR Shareholding
13th Dec 20184:40 pmRNSDirectorate Change
11th Dec 20182:52 pmRNSDirector/PDMR Shareholding
30th Nov 20189:35 amRNSTotal Voting Rights
23rd Nov 20184:05 pmRNSDirector/PDMR Shareholding
21st Nov 201810:46 amRNSDirector/PDMR Shareholding
20th Nov 20187:00 amRNSHalf-year Report
8th Nov 20184:08 pmRNSHolding(s) in Company
31st Oct 20189:57 amRNSTotal Voting Rights
10th Oct 20187:00 amRNSTrading Statement
2nd Oct 20187:00 amRNSAcquisition
28th Sep 201810:42 amRNSTotal Voting Rights
21st Sep 201812:27 pmRNSDirector/PDMR Shareholding
17th Sep 201810:07 amRNSAnnual Financial Report
13th Sep 20188:21 amRNSAcquisition
31st Aug 20189:53 amRNSTotal Voting Rights
24th Aug 20187:00 amRNSDirectorate Change
7th Aug 201811:59 amRNSBlock listing Interim Review
31st Jul 201810:11 amRNSTotal Voting Rights
26th Jul 20183:26 pmRNSBlock listing Interim Review
17th Jul 20182:46 pmRNSResult of AGM
17th Jul 20187:00 amRNSAGM Statement
10th Jul 20184:08 pmRNSAdditional Listing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.